Prior COVID-19 infection may increase risk for developing endothelial dysfunction following hematopoietic cell transplantation.

Autor:	Ariagno S; Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, United States., Ragoonanan D; Division of Pediatrics, Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Khazal S; Division of Pediatrics, Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Mahadeo KM; Division of Pediatrics, Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Cisneros GS; Pediatric Hematology and Oncology, University of California San Francisco, San Francisco, CA, United States., Zinter MS; Pediatric Critical Care Medicine, University of California San Francisco, San Francisco, CA, United States., Blacken RA; Cancer and Blood Disorders Center, Boston Children's Hospital, Boston, MA, United States., Mohan G; Pediatric Critical Care, Massachusetts General Hospital, Boston, MA, United States.; Hematology-Oncology, Boston Children's Hospital, Boston, MA, United States., Lehmann LE; Pediatric Stem Cell Transplant, Dana Farber Cancer Institute/Boston Children's Hospital, Boston, MA, United States., Ferdjallah A; Pediatric Hematology and Oncology, Mayo Clinic, Rochester, MN, United States., Mara KC; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, United States., Kohorst MA; Pediatric Hematology and Oncology, Mayo Clinic, Rochester, MN, United States.
Jazyk:	angličtina
Zdroj:	Frontiers in oncology [Front Oncol] 2023 Jan 17; Vol. 12, pp. 1000215. Date of Electronic Publication: 2023 Jan 17 (Print Publication: 2022).
DOI:	10.3389/fonc.2022.1000215
Abstrakt:	Endothelial dysfunction underlies many of the major complications following hematopoietic cell transplantation (HCT), including transplant-associated thrombotic microangiopathy (TA-TMA), veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS), and engraftment syndrome (ES). Emerging evidence similarly implicates endothelitis and microangiopathy in severe COVID-19-related multi-system organ dysfunction. Given the overlap in these two illness states, we hypothesize that prior COVID-19 infection may increase risk for HCT-related endotheliopathies. This retrospective, multicenter study included patients aged 0-25 years who underwent autologous or allogeneic HCT for any indication between January 1, 2020 and September 21, 2021, with close attention to those infected with COVID-19 in either the six months prior to transplant or twelve months following transplant. Incidences of TA-TMA, VOD/SOS, and ES were compared among patients with COVID-19 infection pre-HCT and post-HCT, as well as with historical controls who were never infected with SARS-CoV-2. Those who underwent HCT following COVID-19 infection displayed significantly increased rates of TA-TMA compared to those who were never infected. Additionally, our data suggests a similar trend for increased VOD/SOS and ES rates, although this did not reach statistical significance. Therefore, a history of COVID-19 infection prior to undergoing HCT may be a nonmodifiable risk factor for endothelial-related complications following HCT. Further studies are warranted to better clarify this relationship among larger cohorts and in the era of the Omicron SARS-CoV-2 variants. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Ariagno, Ragoonanan, Khazal, Mahadeo, Cisneros, Zinter, Blacken, Mohan, Lehmann, Ferdjallah, Mara and Kohorst.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu